Antineoplastic and Immunomodulating Agents

DRUG2 trials

Sponsors

Groupe Hospitalier Pitie-Salpetriere, University Hospital, Caen

Conditions

CancerCardiac Disease

Unknown Phase

Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)

CompletedNCT03530215

Groupe Hospitalier Pitie-SalpetriereCancer, Cardiac Disease

Start: 2018-05-02End: 2023-04-08Updated: 2023-04-13

Evaluation of Reporting of AdVerse Events Associated With AnTicAncer theRapy (AVATAR)

University Hospital, CaenCancer

Start: 2021-01-01End: 2025-01-01Target: 5000000Updated: 2021-01-06

Related Papers

Immune checkpoint inhibitor rechallenge after immune-related adverse events: a retrospective study from VigiBase update in 2024 looking for emergent safety signals

BMJ Open2024-12-015 citations

Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study

European Heart Journal2021-05-2675 citations

Anticancer drugs associated with venous thromboembolic event: Analysis of the WHO pharmacovigilance database.

Journal of Clinical Oncology2021-05-20

Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase

Circulation2020-10-23219 citations

Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database

European Heart Journal - Cardiovascular Pharmacotherapy2020-04-2275 citations

Cardiovascular Toxicities Associated With Ibrutinib

Journal of the American College of Cardiology2019-09-23250 citations